Ftse Mib
36.206,48
0,02%
DAX
21.219,74
-0,78%
S&P 500
6.101,24
-0,29%
NASDAQ
19.954,30
0,00%
Bitcoin
100.927,58
-3,57%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Oncocyte Corporation (OCX) Oncocyte Corporation (OCX) Notizie

OCX

Oncocyte (OCX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OCX
DataOraFonteTitoloSimboloCompagnia
08/01/202522:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
08/01/202514:30GlobeNewswire Inc.Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerNASDAQ:OCXOncocyte Corporation
06/01/202522:05GlobeNewswire Inc.Oncocyte Expands Market Opportunity for VitaGraft™ KidneyNASDAQ:OCXOncocyte Corporation
09/12/202422:05GlobeNewswire Inc.Oncocyte to Participate in “J.P. Morgan Week” and Host Investor MeetingsNASDAQ:OCXOncocyte Corporation
09/12/202414:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCXOncocyte Corporation
04/12/202422:15GlobeNewswire Inc.Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyNASDAQ:OCXOncocyte Corporation
02/12/202422:05GlobeNewswire Inc.Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms NASDAQ:OCXOncocyte Corporation
12/11/202422:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCXOncocyte Corporation
12/11/202422:05GlobeNewswire Inc.Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025NASDAQ:OCXOncocyte Corporation
06/11/202422:45GlobeNewswire Inc.Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12NASDAQ:OCXOncocyte Corporation
22/10/202422:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OCXOncocyte Corporation
22/10/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OCXOncocyte Corporation
18/10/202422:55Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:OCXOncocyte Corporation
16/10/202423:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OCXOncocyte Corporation
16/10/202422:15GlobeNewswire Inc.Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los AngelesNASDAQ:OCXOncocyte Corporation
08/10/202422:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:OCXOncocyte Corporation
08/10/202414:30GlobeNewswire Inc.Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical TrialNASDAQ:OCXOncocyte Corporation
03/10/202400:41GlobeNewswire Inc.Oncocyte Signs Leading Transplant Centers in US and GermanyNASDAQ:OCXOncocyte Corporation
03/10/202400:35GlobeNewswire Inc.Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesNASDAQ:OCXOncocyte Corporation
25/09/202422:09Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OCXOncocyte Corporation
20/08/202415:00GlobeNewswire Inc.PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics TechnologyNASDAQ:OCXOncocyte Corporation
12/08/202422:10GlobeNewswire Inc.Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series StudyNASDAQ:OCXOncocyte Corporation
09/08/202412:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OCXOncocyte Corporation
08/08/202422:05GlobeNewswire Inc.Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 ResultsNASDAQ:OCXOncocyte Corporation
05/08/202422:05GlobeNewswire Inc.Oncocyte Announces August Investor Conferences ParticipationNASDAQ:OCXOncocyte Corporation
01/08/202422:05GlobeNewswire Inc.Oncocyte to Announce Second Quarter 2024 Financial Results on August 8NASDAQ:OCXOncocyte Corporation
11/07/202414:00GlobeNewswire Inc.MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" EpisodeNASDAQ:OCXOncocyte Corporation
24/06/202418:41GlobeNewswire Inc.Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership MoveNASDAQ:OCXOncocyte Corporation
17/06/202422:05GlobeNewswire Inc.Oncocyte Appoints Andrea James as Chief Financial OfficerNASDAQ:OCXOncocyte Corporation
03/06/202420:13GlobeNewswire Inc.Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft StudyNASDAQ:OCXOncocyte Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OCX

La tua Cronologia

BIT
BMPS
Banca Monte Dei Paschi D...
BIT
UCG
Unicredit
BIT
PRY
Prysmian
BIT
ENEL
Enel
BIT
ISP
Intesa Sanpaolo
BIT
STMMI
ST Microelectronics
BIT
G
Generali
BIT
RACE
Ferrari NV
BIT
MB
Mediobanca Banca di Cred...
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
LDO
Leonardo
BIT
BAMI
Banco BPM
BIT
SRG
Snam
BIT
BPE
Bper Banca
BIT
SPM
Saipem
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network